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LETTERS TO THE EDITOR
High dialysate calcium may
improve the efficacy of
calcimimetic treatment in
hemodialysis patients with
severe secondary
hyperparathyroidism
To the Editor: In a recent issue of Kidney International,
Szczech et al [1] indicated that in the cinacalcet phase III
studies “management of phosphorus binders and vitamin
D sterols were left to the clinical discretion of the site in-
vestigators in each of these trials,” and in this context, the
doses of phosphate binders and vitamin D analogs were
not significantly different during the study and between
study groups. In our opinion, this statement is an over-
simplification. The hemodialysis patients of these trials
[2–4] had inadequately controlled hyperparathyroidism
despite optimal standard treatment. They were assigned
to receive cinacalcet or placebo to achieve intact parathy-
roid hormone (iPTH) serum values of ≤250 pg/mL. A
modification of phosphate binder or vitamin D analog
doses was only permitted if plasma iPTH, calcium, or
phosphorus were outside the normal range. The optimal
combination of these compounds and dialysate calcium
has not been specifically assessed in these studies.
We evaluated the possible importance of a high
dialysate calcium concentration. We administered
cinacalcet for 6 months to 7 chronic hemodialysis pa-
tients with severe secondary hyperparathyroidism, using
a dialysate calcium concentration of 1.75 mmol/L. The av-
erage reduction of plasma parathyroid hormone (PTH)
obtained was 60% (Fig. 1), with only 30 mg/day of cinacal-
cet in 6 patients, and 60 mg/day in 1 and low doses of cal-
cium carbonate, sevelamer, and/or alfacalcidol. Plasma
calcium and phosphorus decreased slightly.
Thus, severe secondary uremic hyperparathyroidism
can be controlled with small doses of cinacalcet in pa-
tients on high calcium dialysate, together with moderate
doses of oral calcium and vitamin D.
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Reply from the Authors
The authors of this letter provide additional detail to my
summary of the trials comparing cinacalcet to placebo [1].
They are correct in that these trials were not specifically
designed to assess the optimal combination of cinacalcet,
vitamin D analogs, and phosphorus binders [2–4]. To the
extent that each protocol allowed changes in the latter 2
groups of medications, there were no differences between
study groups. The data presented by the authors of this
letter are compelling and suggest an additional avenue to
pursue toward defining potential strategies for the control
of secondary hyperparathyroidism.
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